DermTech, Inc. (DMTK)
| Market Cap | 1.09B |
| Revenue (ttm) | 9.13M |
| Net Income (ttm) | -51.00M |
| Shares Out | 29.61M |
| EPS (ttm) | -2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 806,476 |
| Open | 35.11 |
| Previous Close | 34.94 |
| Day's Range | 34.63 - 36.74 |
| 52-Week Range | 9.85 - 84.49 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 62.00 (+69.0%) |
| Est. Earnings Date | Nov 3, 2021 |
About DMTK
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th...
Financial Performance
In 2020, DermTech's revenue was $5.89 million, an increase of 74.94% compared to the previous year's $3.36 million. Losses were -$35.25 million, 79.0% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DermTech stock is "Strong Buy." The 12-month stock price forecast is 62.00, which is an increase of 68.98% from the latest price.
News
How DermTech Could Change Skin Cancer Testing -- Or Fizzle Out
DermTech's innovative skin treatment is making it easier and cheaper to test for skin cancer, causing the business to grow. Fast.
DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The Journal ...
Should Investors Be Concerned About DermTech?
Be concerned? No. Be patient?
3 Monster Stocks in the Making to Buy Right Now
Their growth prospects are massive.
DermTech Management to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...
3 Growth Stocks Under $50 That Could Double Your Money
You won't need much upfront cash to buy these promising growth stocks.
DermTech to Present at Florida Association of Health Plans 2021 Annual Conference
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it is presenting at the...
DermTech Management to Participate at the Lake Street 2021 BIG5 Conference
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...
Got $100? 3 Smart Growth Stocks to Buy Right Now
A C-note will allow you to pick up shares of all three of these great stocks.
Why Shares of DermTech Dropped 19% in July
The company's noninvasive skin genomics platform has great potential, but its losses have made investors wary.
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 11.11% and 11.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: DermTech Q2 Earnings
Shares of DermTech (NASDAQ:DMTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 1.72% over the past year to ($0.59), which missed the estim...
DermTech Reports Second Quarter 2021 Financial Results
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial resu...
Will DermTech, Inc. (DMTK) Report Negative Earnings Next Week? What You Should Know
DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DermTech to Announce Second Quarter Financial Results on August 4, 2021
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its...
DermTech Announces New San Diego Headquarters
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced expansion pl...
3 Healthcare Stocks That Could Make You Rich
They're disruptors that could change healthcare.
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
All three of them are well-positioned for tremendous growth.
This Medical Device Company Is Changing the Game in Skin Cancer
And it's on sale right now.
DermTech Announces New Appointment of Monica Tellado to its Board of Directors
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Moni...
DermTech CEO John Dobak, M.D. Wins San Diego Business Journal CEO of the Year Award, Public Company, Medium Category
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech CEO, John...
Ditch Dogecoin: These 3 Stocks Could Double Your Money
The path to a twofold or greater return is straightforward for each of these stocks.
DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with re...
DermTech Announces Three New Key Leadership Appointments: Chief Medical Officer, Vice President, Sales and Vice Presi...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today three new key leadershi...
DermTech Announces Three New Scientific Advisory Board Members
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of Dr. Kl...